No Data
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
CCORF Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $65
Express News | CervoMed Announces Last Patient Last Visit in Phase 2B Rewind-Lb Trial of Neflamapimod for the Treatment of Early-Stage Dementia With Lewy Bodies (Dlb)
CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia With Lewy Bodies (DLB)
Express News | CervoMed Inc Files for Mixed Shelf Offering of $250 Mln-SEC Filing
Express News | CervoMed Inc: Not Subject to Any Termination Penalties or Other Expenses Related to Termination of Sales Agreement
No Data
No Data